Jefferies Sees Zalviso Upside for AcelRx (ACRX) Following Pain Survey

Jefferies analyst Biren Amin reiterated a Buy rating and $17 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following a physician survey which offered an optimistic upside scenario for Zalviso.

Amin commented, "We recently surveyed 43 physicians which currently prescribe IV patient-controlled analgesia to their post-surgical pain patients to assess the pot'l adoption of new tx over the next 1-2 years. Zalviso captures mkt share of 22% and 26% share in '15 and '16, respectively, and significantly higher than our mkt share assumptions of 1% and 3%, respectively, which drive our risk-adj sales est of $20 million and $65 million."

For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.

Shares of AcelRx Pharmaceuticals closed at $10.10 yesterday.

You May Also Be Interested In

• Mr. Cooper Group Inc. (COOP) PT Raised to $87 at Jefferies
• KKR Real Estate Financial Trust (KREF) PT Lowered to $12 at JMP Securities
• Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank